SPRB Company Profile and Key Details

Q: Who are the executives of SPRB?

Dr. Libbie Mansell M.B.A., Ph.D.Chief Regulatory & Quality OfficerDr. Ralph William Charlton III, M.D.Chief Medical OfficerMs. P. J. RamtinSenior Vice President of Bus. OperationsDr. Mojtaba Noursalehi Ph.D.Senior Vice President of BiometricsDr. Javier Szwarcberg M.D., M.P.H.Chief Executive Officer & DirectorMr. Samir M. Gharib CPA, CPA, M.B.A.Pres & Chief Financial Officer

NASDAQ : SPRB

Spruce Biosciences

$54.21

-0.735-1.34%

At Close 4:00 PM

58.74

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Spruce Biosciences, Inc. (SPRB) stock declined over -1.34%, trading at $54.21 on NASDAQ, down from the previous close of $54.94. The stock opened at $53.86, fluctuating between $51.93 and $55.10 in the recent session.

Stock Snapshot

54.94

Prev. Close

31.46M

Market Cap

51.925

Day Low

-0.64

P/E Ratio

-84.32

EPS (TTM)

-0.81

Cash Flow per Share

53.86

Open

580.35K

Number of Shares

55.1

Day High

59.2%

Free Float in %

1.86

Book Value

23.87K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 02, 2026	53.86	55.00	51.78	54.21	23.87K
Feb 27, 2026	59.27	59.34	54.94	54.94	15.6K
Feb 26, 2026	58.91	60.11	57.00	58.55	17.54K
Feb 25, 2026	59.10	62.94	58.00	58.73	38.22K
Feb 24, 2026	54.02	60.00	53.95	58.22	34.74K
Feb 23, 2026	51.00	55.27	48.50	53.58	41.2K
Feb 20, 2026	52.80	54.27	48.08	49.72	41.38K
Feb 19, 2026	53.01	53.47	49.12	52.62	58.19K
Feb 18, 2026	60.76	65.00	51.14	53.48	260.44K
Feb 17, 2026	65.42	65.42	51.59	58.25	134.53K
Feb 13, 2026	80.05	83.54	66.08	66.29	61.89K
Feb 12, 2026	80.00	84.38	78.30	82.96	25.22K
Feb 11, 2026	86.01	86.95	81.00	82.69	47.05K
Feb 10, 2026	77.24	86.62	75.59	83.63	41K
Feb 09, 2026	71.96	81.30	71.96	79.07	51.19K
Feb 06, 2026	71.17	74.40	71.00	72.40	29.86K
Feb 05, 2026	77.57	78.02	69.02	70.85	32.37K
Feb 04, 2026	80.89	81.40	75.10	79.23	19.76K
Feb 03, 2026	78.96	83.49	78.00	83.49	30.91K
Feb 02, 2026	76.76	78.23	76.00	77.99	18.35K

Contact Details

Daly City, CA 94014

United States

https://www.sprucebiosciences.com 415 655 4168

About Company

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Stock Peers

REGN

9.14+1.17%

Regeneron Pharmaceuticals, Inc.$790.81 ARGX

-10.16-1.32%

argenx SE$756.76 UTHR

9.92+1.97%

United Therapeutics Corporation$513.82 VRTX

-10.8-2.17%

Vertex Pharmaceuticals Incorporated$486.03 MDGL

3.62+0.84%

Madrigal Pharmaceuticals, Inc.$435.62 PRAX

-6.16-1.83%

Praxis Precision Medicines, Inc.$330.59 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-7.85-2.36%

Alnylam Pharmaceuticals, Inc.$325.07 KRYS

-16.83-6.11%

Krystal Biotech, Inc.$258.81 ASND

8.59+3.68%

Ascendis Pharma A/S$242.09

Company Overview

Spruce Biosciences, Inc. (NASDAQ:SPRB) closed at $54.20 USD, losing -$0.73 (-1.34%) from the previous close of $54.94. The stock is currently mid-range between its 52-week high and low $7.00 and $2.33 thousand. With a market capitalization of about $31.46 million, Spruce Biosciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.61). Key stats such as the average daily volume over the past year has been around 46.94 thousand shares, volume is running light vs its 52-week average. Headquartered in Daly City, CA, Spruce Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Javier Szwarcberg, the company employs approximately 20 people and listed since October 09, 2020. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.

Technical Performance

SPRB has shown weak momentum, losing -8.15% over the past week and -54.72% over the past quarter, though year-to-date performance is down -17.97%. Short-term trend indicators are mixed aligned (SMA20 -15.09%, SMA50 -22.85%, SMA200 12.84%). The stock’s 14-day RSI is 39.33 (weak momentum), while the ATR of 7.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.6% below its high and over 1269.59% above its low. Average 10-day trading volume of 30.36 thousand shares is below the 3-month average of 47.72 thousand, indicating normal recent market interest.

Valuation Metrics

Spruce Biosciences, Inc. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 44.34 and a price-to-book ratio of 5.57 trading at moderately above to book value. The P/FCF stands at -0.65, also above market averages.

Dividend & Fair Value

Spruce Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $73.14. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Spruce Biosciences, Inc. generated EPS of -$84.76 over the past year. Five-year average earnings growth is -17.92%. Wall Street analysts project EPS growth of 38.81% annually over the next five years. The latest quarter delivered EPS of -$14.58. The next quarter is forecast at -$9.16. Next year's EPS is expected at -$3.35. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $283.00 to $160.00. The high target offers 422.14% upside. The low target suggests 195.2% downside. The mean target is $222.29. This offers 310.13% upside. Spruce Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by -6.3%. The prior quarter beat by -80.61%. Over the last six quarters, Apple has recorded several small beats. These include -32.41% in August 12, 2024.

Shareholding & Insider Activity

Spruce Biosciences, Inc. has 563.08 thousand shares outstanding. The public float is 561.91 thousand shares, elevated short interest at 1.23% of float. This equals 6.83 thousand shares. The short ratio is 0.31 days. Institutional investors hold 44.95% of the float. Insiders own 8.68%. Novo Holdings A/S holds 2.55 million shares, Chaya Moghrabi Dina has 2.16 million shares and Omega Fund VI, L.P. has 2.16 million shares. Over the past six months, insider transactions show net selling. They sold 25.00 shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Spruce Biosciences generated $10.09M in revenue, or $0.26 per share. Gross margin was 99.31%, operating margin -515.34%, and net profit margin -474.96%. Returns are negative, with ROA at -46.10% and ROE at -62.63%.
On valuation metrics, Spruce Biosciences trades at a P/E of -0.63, P/S of 44.34 and P/B of 5.57. The current ratio is 1.54 and quick ratio is 1.54. Debt-to-equity is 0.19, supported by a cash flow-to-debt ratio of -45.76.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Spruce Biosciences posted revenue of $10.09M, down slightly from $0.00 in the prior quarter. Gross profit was $10.02M (margin 99.31%). Operating income was - $51.99M (margin -515.3%). Net income was- $47.92M (EPS - $1.24).
The company ended the quarter with $96.34M in cash and short-term investments, a total debt of $4.61M, and net debt of - $91.73M. Total assets were $103.95M, with equity of $76.51M. Financials further reflected weakness, with operating cash flow of - $33.28M, free cash flow of - $33.28M, and capital expenditures of - $7.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Spruce Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.81%, with price expected at $48.35 by March 13, 2026, within a range of $38.67 to $58.30 3-Month Outlook: Projected fall of -94.89%, reaching $2.77 by May 28, 2026, with a range of $0.00 to $5.34. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 26, 2027, within a range of $0.00 to $12.78.

Key Takeaways

Spruce Biosciences, Inc. (NASDAQ:SPRB) shares are down -17.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Spruce Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $61.67, suggesting 13.76% upside. Our AI forecast model points to short-term weakness (-10.81% over two weeks), a medium-term fall (-94.89% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Spruce Biosciences, Inc. (SPRB) stock price?

Spruce Biosciences, Inc. (NASDAQ: SPRB) stock price is $54.21 in the last trading session. During the trading session, SPRB stock reached the peak price of $55.10 while $51.93 was the lowest point it dropped to. The percentage change in SPRB stock occurred in the recent session was -1.34% while the dollar amount for the price change in SPRB stock was - $0.74.

SPRB's industry and sector of operation?

The NASDAQ listed SPRB is part of Biotechnology industry that operates in the broader Healthcare sector. Spruce Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SPRB?

Dr. Libbie Mansell M.B.A., Ph.D.
Chief Regulatory & Quality Officer
Dr. Ralph William Charlton III, M.D.
Chief Medical Officer
Ms. P. J. Ramtin
Senior Vice President of Bus. Operations
Dr. Mojtaba Noursalehi Ph.D.
Senior Vice President of Biometrics
Dr. Javier Szwarcberg M.D., M.P.H.
Chief Executive Officer & Director
Mr. Samir M. Gharib CPA, CPA, M.B.A.
Pres & Chief Financial Officer

How SPRB did perform over past 52-week?

SPRB's closing price is 674.36% higher than its 52-week low of $7.00 where as its distance from 52-week high of $2,334.38 is -97.68%.

How many employees does SPRB have?

Number of SPRB employees currently stands at 20.

Link for SPRB official website?

Official Website of SPRB is: https://www.sprucebiosciences.com

How do I contact SPRB?

SPRB could be contacted at phone 415 655 4168 and can also be accessed through its website. SPRB operates from 2001 Junipero Serra Boulevard, Daly City, CA 94014, United States.

How many shares of SPRB are traded daily?

SPRB stock volume for the day was 23.87K shares. The average number of SPRB shares traded daily for last 3 months was 46.94K.

What is the market cap of SPRB currently?

The market value of SPRB currently stands at $31.46M with its latest stock price at $54.21 and 580.35K of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	20
Beta	3.61
Sales or Revenue	$10.09M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SPRB Company Profile and Key Details

Spruce Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Dividend & Fair Value

Price Forecast & Outlook

Valuation Metrics